Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption.
- 10 October 1995
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 92 (21), 9829-9833
- https://doi.org/10.1073/pnas.92.21.9829
Abstract
The delivery of viral vectors to the brain for treatment of intracerebral tumors is most commonly accomplished by stereotaxic inoculation directly into the tumor. However, the small volume of distribution by inoculation may limit the efficacy of viral therapy of large or disseminated tumors. We have investigated mechanisms to increase vector delivery to intracerebral xenografts of human LX-1 small-cell lung carcinoma tumors in the nude rat. The distribution of Escherichia coli lacZ transgene expression from primary viral infection was assessed after delivery of recombinant virus by intratumor inoculation or intracarotid infusion with or without osmotic disruption of the blood-brain barrier (BBB). These studies used replication-compromised herpes simplex virus type 1 (HSV; vector RH105) and replication-defective adenovirus (AdRSVlacZ), which represent two of the most commonly proposed viral vectors for tumor therapy. Transvascular delivery of both viruses to intracerebral tumor was demonstrated when administered intraarterially (i.a.) after osmotic BBB disruption (n = 9 for adenovirus; n = 7 for HSV), while no virus infection was apparent after i.a. administration without BBB modification (n = 8 for adenovirus; n = 4 for HSV). The thymidine kinase-negative HSV vector infected clumps of tumor cells as a result of its ability to replicate selectively in dividing cells. Osmotic BBB disruption in combination with i.a. administration of viral vectors may offer a method of global delivery to treat disseminated brain tumors.Keywords
This publication has 18 references indexed in Scilit:
- Gene Expression from Recombinant Viral Vectors in the Central Nervous System after Blood-Brain Barrier DisruptionNeurosurgery, 1995
- Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.Proceedings of the National Academy of Sciences, 1994
- Delivery of Virus-sized Iron Oxide Particles to Rodent CNS NeuronsNeurosurgery, 1994
- A model system for in vivo gene transfer into the central nervous system using an adenoviral vectorNature Genetics, 1993
- In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain TumorsScience, 1992
- Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: A light and electron microscopic studyExperimental Neurology, 1992
- Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrierJournal of Neurosurgery, 1991
- Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.Proceedings of the National Academy of Sciences, 1989
- β-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouseVirology, 1988
- Ribonucleotide Reductase Encoded by Herpes Simplex Virus Is a Determinant of the Pathogenicity of the Virus in Mice and a Valid Antiviral TargetJournal of General Virology, 1988